We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RTO:NYSERentokil Initial plc Analysis

Data as of 2026-04-29 - not real-time

$33.44

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Rentokil Initial (RTO) is trading in a clear bullish technical environment – the short‑term moving average sits above the medium‑term average and price remains above the 200‑day trend line, while volume is on an upward trajectory. The RSI hovers around the mid‑range, suggesting momentum is neither overbought nor oversold, and the MACD histogram is slightly negative, hinting at a modest pull‑back within the broader uptrend. Fundamentally, the company delivers steady revenue growth and solid operating margins, but its valuation metrics are stretched – the price‑earnings multiple sits well above the industry average and the discounted cash‑flow model implies a price considerably lower than current levels. Recent earnings calls highlighted modest organic growth and reaffirmed the dividend, yet the payout ratio exceeds 100%, raising questions about dividend sustainability. Market sentiment is buoyant, reflected by an extreme greed reading on the fear‑and‑greed index, but the upside potential relative to fair value remains limited. Overall, the stock presents a mixed picture of technical strength tempered by valuation concerns.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish SMA crossover and rising volume
  • Valuation significantly above DCF fair value
  • High payout ratio challenges dividend sustainability

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Steady revenue and operating margin expansion
  • Potential price correction toward fair value
  • Resilient demand for pest control and hygiene services

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Global footprint diversifies revenue streams
  • Moderate beta suggests lower market volatility
  • Long‑term growth prospects balanced by high valuation multiples

Key Metrics & Analysis

Financial Health

Revenue Growth5.80%
Profit Margin6.80%
P/E Ratio58.7
ROE5.38%
ROA3.96%
Debt/Equity112.00
P/B Ratio3.1
Op. Cash Flow$972.0M
Free Cash Flow$828.0M
Industry P/E30.8

Technical Analysis

TrendBullish
RSI53.8
Support$30.60
Resistance$34.67
MA 20$33.43
MA 50$32.12
MA 200$28.54
MACDBearish
VolumeIncreasing
Fear & Greed Index89.59

Valuation

Fair Value$20.84
Target Price$36.10
Upside/Downside7.95%
GradeOvervalued
TypeBlend
Dividend Yield1.85%

Risk Assessment

Beta0.72
Volatility24.98%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.